Increasing Transparency in Generic Drug Applications Act
Summary
Increasing Transparency in Generic Drug Applications Act This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
Bill status
in committee
1 of 4 stages cleared
Introduction
May 2022
Committee Review
Floor Vote
President
Introduced May 26, 2022
Last action May 26, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
May 26, 2022
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
upper
May 26, 2022
Introduced
Introduced in Senate
upper
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about S 4338
Scope: US
Hi! I can help you understand S 4338. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline